GlassScriptPhysician profile
Raphael Bonita
NPI 1790973147
$2,734.51
in general payments reported to CMS, 2019-2025
18 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.68 · 2020: $528 · 2021: $508 · 2022: $552 · 2023: $590 · 2024: $213 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $659 · Consulting Fee: $356 · Education: $59.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $658.86 |
| Consulting Fee | $355.83 |
| Education | $59.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $1,256.57 | 2019-2025 | Optimizer, Optimizer |
| Zoll Medical Corporation | $355.83 | 2023 | |
| Becton, Dickinson and Company | $350.00 | 2021 | |
| Abiomed | $132.91 | 2021-2022 | |
| Abbott Laboratories | $115.89 | 2019-2025 | Mitraclip |
| Alnylam Pharmaceuticals INC. | $114.00 | 2021-2025 | Amvuttra |
| Merck Sharp & Dohme LLC | $87.58 | 2021-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $85.46 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.46 | 2022-2025 | Jardiance |
| Akcea Therapeutics, INC. | $25.23 | 2019 | |
| Novo Nordisk INC | $24.24 | 2023 | Ozempic, Rybelsus |
| Lexicon Pharmaceuticals, INC. | $23.19 | 2023 | Inpefa |
| Amgen INC. | $22.81 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.50 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.88 | 2024 | Camzyos |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $19.08 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.91 | 2023 | Farxiga |
| Pfizer INC. | $11.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Bonita listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.